CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Amneal Pharmaceuticals, Inc. (AMRX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Amneal Pharmaceuticals, Inc. (AMRX)

Pharmaceutical Preparations · market cap $6.1B · as of 2026-07-13

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
9
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Amneal Pharmaceuticals (AMRX) is one of the largest U.S. generic drug manufacturers, generating $3.0B in 2025 revenue across a broad generics and specialty portfolio. The company carries $2.38B in net debt against $197.7M in cash (~22 months runway), and its pipeline is composed almost entirely of Phase 3 generic/505(b)(2) candidates rather than novel therapeutics. The next public event is an earnings release on 2026-08-04.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
Phenazopyridine Hydrochloride Tables, USPPhase 3Uncomplicated Urinary Tract Infections
Testosterone Topical Gel, Metered PumpPhase 3Primary Hypogonadism
Estradiol VaginalPhase 3Atrophic Vaginitis Due to Menopause
Asenapine SublingualPhase 3Schizophrenia
Imatinib MesylatePhase 3Chronic Myeloid Leukemia
Phenazopyridine HydrochloridePhase 3Pain
Test - Bimatoprost OphthalmicPhase 3Glaucoma, Open-Angle
Diclofenac Sodium TopicalPhase 3Osteoarthritis
Mometasone Furoate NasalPhase 3Seasonal Allergic Rhinitis
Price & technical context
3-month
+19.4%
6-month
+72.2%
12-month
+84.9%
52-wk range
$11.52–$21.88
vs 50-day MA
+6.7%
vs 200-day MA
+31.7%
Realized vol
35.1%
Max drawdown
-24.6%

Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for AMRX (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.